AMAG Pharmaceuticals — Q2 2020 Earnings Presentation
16 slides from AMAG Pharmaceuticals's earnings presentation, Aug 6, 2020
Slide 1: AMAG Pharmaceuticals Second Quarter 2020 Financial Results
AMAG Pharmaceuticals Second Quarter 2020 Financial Results August 6, 2020 © 2020 AMAG Pharmaceuticals, Inc. All rights reserved 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, expectations
Slide 3: Agenda
1 Making Progress Against our Strategic Evolution 2 Managing our Core Business AGENDA 3 Financial Update 4 Q&A © 2020 AMAG Pharmaceuticals, Inc. All rights reserved 3
Slide 4: Making Progress Against Strategic Evolution
Making Progress Against Strategic Evolution Recent accomplishments help sharpen focus on future value drivers Building • Scott Myers appointed President & CEO on April 28, 2020 • Tony Casciano promoted to Chief Operating Officer Management Team • Brian Piekos promoted to Chief Financial Officer to L
Slide 5: Engagement During COVID-19
Engagement During COVID-19 Protect the health of our employees AMAG’s Guiding Principles Do our part to stop the spread of COVID-19 During COVID-19 Support our customers and providers by helping them to focus on direct patient care Corporate Functions Remain Engaged • Supply chain remains intact • R
Slide 6: Makena Update: FDA Still Reviewing Pertinent Information
Makena Update: FDA Still Reviewing Pertinent Information AMAG is committed to generating additional information on efficacy Earlier this spring, AMAG submitted a proposal to the FDA to 1. RETROSPECTIVE STUDY generate additional data. The company proposed two Using secondary data sources observationa
Slide 7: Makena Revenue Slightly Impacted by COVID in the Quarter
Managing Our Core Business Makena Revenue Slightly Impacted by COVID in the Quarter SECOND QUARTER REVENUE EXFACTORY TRENDS (doses) • Q2‐2020 ExFactory volume • Q2‐2020 Revenue of $22.3M $30.6 was 27% below Q2‐2019 was 5% below Q1 20201 $22.3 • Q2‐2020 Market Share of 66% • Q2 ‐2020 Average share wa
Slide 8: Feraheme Revenue Impacted by COVID; Returned to Growth in June
Managing Our Core Business Feraheme Revenue Impacted by COVID; Returned to Growth in June SECOND QUARTER REVENUE EXFACTORY TRENDS (grams) $42.1 • Q2‐2020 Revenue of $29.6M • $29.6 Q2 –2020 ExFactory volume was 30% below Q2‐2019 was 26% below Q1‐ 20201 • Q2 ‐2020 Market share of 17.3% • June 2020 ExF
Slide 9: Second Quarter Financial Results
Second Quarter Financial Results $M Q2-2020 Q2-2019 Feraheme $29.6 $42.1 Makena 22.3 30.6 • Revenues Intrarosa 1.2 4.9 – Decrease primarily due to negative impact of Other (0.4) 0.2 COVID‐19 during quarter and the October 2019 unfavorable FDA Advisory Committee Total revenues $52.8 $77.8 recommendat
Slide 10: Reissued Guidance Confirms a Return to Positive Adjusted EBITDA
Reissued Guidance Confirms a Return to Positive Adjusted EBITDA 2020 FINANCIAL GUIDANCE1 ($M) Total revenue $225 ‐ $255 Operating loss $(40) ‐ $(15) Adjusted EBITDA2 $(5) ‐ $20 Risk‐adjusted topline view S, G&A expenses reduced by R&D expenses reduced due to given uncertainty caused by: ~$100M vs. 2
Slide 11: 2020: Goals and Key Areas of Focus for AMAG
2020: Goals and Key Areas of Focus for AMAG GOALS Successful CEO transition COMPLETED Divest Intrarosa® and Vyleesi® to align with the new strategic direction Completed exclusive licensing agreement with Norgine for ciraparantag Advance AMAG-423 and Drive continued Maintain patient access to cirapar
Slide 12: AMAG Pharmaceuticals Q&A
AMAG Pharmaceuticals Q&A © 2019 AMAG Pharmaceuticals, Inc. All© rights 2020 reservedAMAG Pharmaceuticals, Inc. All rights reserved 12
Slide 13: Appendix
Appendix 13
Slide 14: Reconciliation of GAAP to Non-GAAP Financial Results
Reconciliation of GAAP to Non-GAAP Financial Results ($M) YTD-2020 YTD-2019 Q2-2020 Q2-2019 GAAP operatingloss ($24.8) ($234.2) ($7.0) ($116.2) Depreciation andintangible asset amortization 19.7 9.1 9.4 4.7 Stock‐based compensation 5.9 8.7 2.1 4.5 Restructuring 8.2 7.4 8.2 ‐‐ Gain on Asset Sale (14.
Slide 15: Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance
Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance ($M) 2020 Financial Guidance GAAP operating income $(40) - $(15) Depreciation & intangible asset amortization 30 Stock‐based compensation 11 Restructuring 8.2 Gain on sale of assets (14.4) Non-GAAP adjusted EBITDA $(5) - $20 APPENDIX © 2020
Slide 16: AMAG Pharmaceuticals Second Quarter 2020 Financial Results
AMAG Pharmaceuticals Second Quarter 2020 Financial Results August 6, 2020 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2020 reservedAMAG Pharmaceuticals, Inc. All rights reserved 16